Skip to main
ARQT
ARQT logo

Arcutis Biotherapeutics (ARQT) Stock Forecast & Price Target

Arcutis Biotherapeutics (ARQT) Analyst Ratings

Based on 11 analyst ratings
Buy
Strong Buy 45%
Buy 45%
Hold 9%
Sell 0%
Strong Sell 0%

Bulls say

Arcutis Biotherapeutics Inc. is poised for strong growth, evidenced by a projected 4% price increase for the Zoryve franchise and impressive near-term prescription growth of approximately 12% quarter over quarter. The company's product revenue for Zoryve reached $69.4 million in the fourth quarter, surpassing early estimates and indicating a robust sales trajectory driven by the launch of Zoryve foam and cream formulations. Management is optimistic about sustained revenue growth in 2025 and beyond, supported by new indications and label extensions that position Zoryve as a leading treatment option among dermatologists for various skin conditions.

Bears say

Arcutis Biotherapeutics Inc. has reported a significant decline in R&D expenses, which fell by 39.1% year-over-year to $14.5 million, indicating potential challenges in maintaining momentum for its product development despite previous trial successes. The company also recorded a net loss of $10.8 million in the fourth quarter of 2024, resulting in a diluted loss per share of $0.09, which was lower than previously estimated and reflects the ongoing financial strain as it navigates increasing operating expenses without providing operational expenditure guidance. Additional risks, such as reliance on a third party for manufacturing Zoryve and the highly competitive dermatology market, further contribute to a cautious outlook regarding the company’s future commercial success and overall financial health.

Arcutis Biotherapeutics (ARQT) has been analyzed by 11 analysts, with a consensus rating of Buy. 45% of analysts recommend a Strong Buy, 45% recommend Buy, 9% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Arcutis Biotherapeutics and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Arcutis Biotherapeutics (ARQT) Forecast

Analysts have given Arcutis Biotherapeutics (ARQT) a Buy based on their latest research and market trends.

According to 11 analysts, Arcutis Biotherapeutics (ARQT) has a Buy consensus rating as of Aug 26, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $34.82, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $34.82, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Arcutis Biotherapeutics (ARQT)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.